Jennifer graduated in 2009 from the University of Bath with a First Class MChem honours degree in Chemistry for Drug Discovery with Industrial Training. She then completed a PhD in Organic Chemistry at the University of Bath, focusing on the asymmetric synthesis of highly substituted lactones for use in natural product synthesis. She joined HGF in May 2016.
Jennifer’s undergraduate degree provided her with a broad understanding of medicinal chemistry, including some aspects of biochemistry and pharmacology. She completed an industrial placement at AstraZeneca where she worked as a Synthetic Organic Chemist in the lead optimisation stage of drug discovery. Her PhD research involved the development of novel methodology for the asymmetric synthesis of building blocks for use in natural product synthesis. This work resulted in three publications and was presented at two international conferences.
After her PhD, Jennifer spent two years working in R&D for a specialist diabetes diagnostics company. This project focused on the design and synthesis of novel boronic acid fluorophore conjugates for use in an HbA1c assay.
Before joining HGF, Jennifer was the Industry Manager for the NIHR Diagnostic Evidence Cooperative based at Imperial College London. During this time, she was responsible for developing a portfolio of industry collaborative clinical studies for Point-of-Care in vitro diagnostic device evaluation.
Chemistry for Drug Discovery
Organic Synthetic Chemistry
Jennifer organised a firm-wide tutorial series for trainee patent attorneys who took the UK qualifying exams in 2018 and 2019. She also regularly attends IP Inclusive events.
Artificial Intelligence (AI) has moved from the realm of science fiction firmly into the mainstream of technological innovation. Trained AI models in some cases are able to perform data analysis …Read article
Mental health and behavioural disorders have a profound impact on wellbeing worldwide, with an estimated 13% of the global population suffering from a mental health or substance use disorder . …Read article
Is the USPTO now stricter than the EPO on antibody claims? A consideration of recent developments from both sides of the pond. Patent protection for monoclonal antibodies, bispecific antibodies and …Read article
Simulations offer a powerful tool in modern-day engineering. Subjecting designs to initial testing in a simulated environment will, for many designs, reduce costs owing to reduced needs to produce and …Read article
Summary Mr Justice Meade has revoked Bristol Myers Squibb’s (BMS) European patent No. EP1427415 (EP’415) and corresponding supplementary protection certificate (SPC) that relate to the compound Apixaban (ELIQUIS) for lack …Read article
After a challenging couple of years, we are delighted to invite you to join us for HGF’s eighth annual IP in Healthcare Conference. We will review the latest intellectual property …Event details
HGF is holding a webinar and an in-person event covering the UPC in Germany and Austria this Spring. The provisional phase of the Unified Patent Court (UPC) is now underway …Event details
HGF is hosting a series of HGF Complete webinars this Spring. Our expert speakers will discuss trade marks and designs in the EU and the UK. We will compare and …Event details
If you would like to discuss how HGF could help you, contact one of our IP specialists.